Oral psilocin could reshape how psychedelic treatments are formulated and delivered. A randomized crossover trial found that administering psilocin directly produced an experience broadly comparable to oral psilocybin, but with a lower overall burden of adverse effects.
Why Researchers Are Looking Beyond Psilocybin
Most contemporary psychedelic trials administer synthetic psilocybin by mouth. Psilocybin is a prodrug, meaning the body must convert it into psilocin before its primary psychoactive effects occur.
That conversion largely takes place in the gastrointestinal tract and liver. Differences in metabolism may contribute to variability in drug exposure, while oral administration can be associated with nausea and other physical effects.
Direct psilocin administration could bypass the conversion step. In theory, that could make treatment effects more predictable, accelerate onset, or reduce the time patients require clinical monitoring. Until now, however, direct psilocin administration had received little modern human research.
A Rare Direct Comparison Of Oral Psilocin
The randomized, within-subject crossover trial enrolled 20 healthy adults between ages 25 and 50. Every participant had prior experience with a substantial psychedelic effect, and the group included 10 women and 10 men.
Participants completed up to four administration sessions separated by four weeks. The primary comparison involved 25 milligrams of botanical oral psilocybin and an equimolar 17.5-milligram dose of botanical oral psilocin. Researchers also tested sublingual psilocin at lower doses.
The formulations were standardized extracts derived from Psilocybe cubensis mushrooms. Each retained small amounts of naturally occurring indole alkaloids alongside a specified dose of psilocybin or psilocin.
All sessions included preparation, continuous psychological support, safety monitoring, and post-session psychotherapy. Researchers tracked vital signs, adverse events, subjective drug intensity, mystical-type experiences, challenging experiences, emotional breakthroughs, and psychological insight.
Similar Experiences With Fewer Adverse Effects
Oral psilocin and oral psilocybin produced broadly similar psychological and physiological profiles. The conditions did not significantly differ in participant-rated intensity, time to peak intensity, cardiovascular measurements, or scores across the study’s principal psychological questionnaires.
The anticipated faster onset of oral psilocin was not observed. Both formulations produced experiences with comparable timing, intensity, and duration.
The clearest distinction involved tolerability. All 18 participants who completed each oral condition reported at least one adverse event. However, the total adverse-event burden, calculated using both frequency and severity, was significantly lower following oral psilocin.
Adverse events after psilocin were all classified as mild. The psilocybin condition included moderate headaches and anxiety, as well as one severe episode involving temporary loss of consciousness. Gastrointestinal adverse-event burden did not significantly differ between the oral formulations.
Psilocin Removes One Metabolic Step
Plasma psilocin concentration has previously been closely associated with serotonin 2A receptor occupancy and subjective psychedelic intensity. Administering psilocin directly removes the need to convert psilocybin into its active metabolite.
This creates a plausible path toward more consistent exposure and improved tolerability. The current trial cannot confirm that mechanism because researchers did not collect pharmacokinetic data. It also remains possible that oral psilocin produced slightly lower effective exposure despite the use of equimolar doses.
The similar psychological and physiological outcomes nevertheless support the possibility that psilocin can reproduce the core acute effects of psilocybin without requiring the same metabolic conversion.
Sublingual Delivery Remains An Open Question
Sublingual psilocin was generally well tolerated, but the conservative doses produced substantially milder effects than oral psilocin. The lower exposure prevented researchers from fairly evaluating whether sublingual delivery could shorten sessions or reduce gastrointestinal effects.
The study also included a small, healthy, highly educated sample and experienced substantial dropout across its three-to-four-session design. Participants could often distinguish the oral conditions from the milder sublingual sessions, weakening blinding. Filament Health supplied the study drugs, funded the trial through the University of California, San Francisco, and contributed to protocol discussions and manuscript review.
A Starting Point For Next-Generation Psychedelic Formulations
These findings do not establish oral psilocin as a treatment for any psychiatric condition. They show that standardized botanical psilocin can produce a controlled psychedelic experience in healthy adults and may offer a modest tolerability advantage over psilocybin.
Larger trials with pharmacokinetic sampling, clinical populations, and optimized sublingual doses are now needed. If the tolerability signal holds, direct psilocin could become an important option for developing more predictable and manageable psychedelic therapies.
Citations
Explore more at https://www.interventionalpsychiatry.org/
